Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Hepatic steatosis and hepatic iron overload modify the association of iron markers with glucose metabolism disorders and metabolic syndrome.

Tytuł:
Hepatic steatosis and hepatic iron overload modify the association of iron markers with glucose metabolism disorders and metabolic syndrome.
Autorzy:
Pitchika A; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
Kühn JP; Institute and Policlinic for Diagnostic and Interventional Radiology, University Hospital, Carl Gustav Carus, TU Dresden, Dresden, Germany.
Schipf S; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.; Department of Medicine A, University Medicine Greifswald, Greifswald, Germany.
Nauck M; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.; German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany.
Dörr M; German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany.; Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
Lerch MM; Department of Medicine A, University Medicine Greifswald, Greifswald, Germany.
Kromrey ML; Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany.
Felix SB; German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany.; Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
Markus MRP; German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany.; Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.; DZD (German Center for Diabetes Research), Site Greifswald, Greifswald, Germany.
Rathmann W; DZD (German Center for Diabetes Research), Site Greifswald, Greifswald, Germany.; Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, German Diabetes Center (DDZ), Institute for Biometrics and Epidemiology, Düsseldorf, Germany.
Völzke H; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.; German Center for Cardiovascular Research (DZHK e.V.), Partner site Greifswald, Greifswald, Germany.; DZD (German Center for Diabetes Research), Site Greifswald, Greifswald, Germany.
Ittermann T; Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
Źródło:
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2021 Aug; Vol. 41 (8), pp. 1841-1852. Date of Electronic Publication: 2021 Mar 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: Malden, MA : Wiley-Blackwell
Original Publication: Oxford, UK : Blackwell Munksgaard, c2003-
MeSH Terms:
Diabetes Mellitus, Type 2*
Iron Overload*
Metabolic Syndrome*/epidemiology
Germany/epidemiology ; Humans ; Iron
References:
Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB The role of iron in type 2 diabetes in humans. Biochimi Biophys Acta. 2009;1790(7):671-681.
Creighton Mitchell T, McClain DA. Diabetes and Hemochromatosis. Curr DiabRep. 2014;14(5):488.
Kunutsor SK, Apekey TA, Walley J, Kain K. Ferritin levels and risk of type 2 diabetes mellitus: an updated systematic review and meta-analysis of prospective evidence. Diabetes Metab Res Rev. 2013;29(4):308-318.
Montonen J, Boeing H, Steffen A, et al. Body iron stores and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetologia. 2012;55(10):2613-2621.
Huth C, Beuerle S, Zierer A, et al. Biomarkers of iron metabolism are independently associated with impaired glucose metabolism and type 2 diabetes: the KORA F4 study. Eur J Endocrinol. 2015;173(5):643-653.
Liu Y, Song J, Tian H, et al. Association of serum ferritin concentrations with prevalence of prediabetes, type 2 diabetes mellitus, and metabolic syndrome in a Chinese population from Sichuan. International Journal of Diabetes in Developing Countries. 2015;35(3):522-528.
Sun L, Franco OH, Hu FB, et al. Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly Chinese. J Clin Endocrinol Metab. 2008;93(12):4690-4696.
Pitchika A, Schipf S, Nauck M, et al. Associations of iron markers with type 2 diabetes mellitus and metabolic syndrome: Results from the prospective SHIP study. Diabetes Res Clin Pract. 2020;163:108149.
Akter S, Nanri A, Kuwahara K, et al. Circulating ferritin concentrations and risk of type 2 diabetes in Japanese individuals. J Diabetes Investig. 2017;8(4):462-470.
Britton LJ, Subramaniam VN, Crawford DH. Iron and non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22(36):8112-8122.
Datz C, Muller E, Aigner E. Iron overload and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42(2):173-183.
Milic S, Mikolasevic I, Orlic L, et al. The Role of iron and iron overload in chronic liver disease. Med Sci Monit. 2016;22:2144-2151.
Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res. 2013;43(1):51-64.
Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9-19.
Fumeron F, Pean F, Driss F, et al. Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3 years: the data from an epidemiological study on the insulin resistance syndrome (DESIR) study. Diabetes Care. 2006;29(9):2090-2094.
Kilani N, Vollenweider P, Waeber G, Marques-Vidal P, et al. Iron metabolism and incidence of metabolic syndrome. Nutr Metab Cardiovasc Dis. 2015;25(11):1025-1032.
John U, Greiner B, Hensel E, et al. Study of health in Pomerania (SHIP): a health examination survey in an East German region: objectives and design. Soz Praventivmed. 2001;46(3):186-194.
Völzke H, Alte D, Schmidt CO, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2010;33(Suppl 1):S62-S69.
Alberti G, et al. The IDF consensus worldwide definition of the metabolic syndrome. Lancet. 2005;366:1059-1062.
Kühn JP, Meffert P, Heske C, et al. Prevalence of fatty liver disease and hepatic iron overload in a Northeastern German population by using quantitative MR imaging. Radiology. 2017;284(3):706-716.
Kühn JP, Hernando D, Muñoz del Rio A, et al. Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology. 2012;265(1):133-142.
Podmore C, Meidtner K, Schulze MB, et al. Association of multiple biomarkers of iron metabolism and type 2 diabetes: The EPIC-InterAct Study. Diabetes Care. 2016;39(4):572-581.
Suárez-Ortegón MF, Ensaldo-Carrasco E, Shi T, McLachlan S, Fernández-Real JM, Wild SH. Ferritin, metabolic syndrome and its components: A systematic review and meta-analysis. Atherosclerosis. 2018;275:97-106.
Kim CH, Kim HK, Bae SJ, Park JY, Lee KU. Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. Metabolism. 2011;60(3):414-420.
Kang HT, Linton JA, Shim JY. Serum ferritin level is associated with the prevalence of metabolic syndrome in Korean adults: the 2007-2008 Korean national health and nutrition examination survey. Clin Chim Acta. 2012;413(5-6):636-641.
Orban E, Schwab S, Thorand B, Huth C. Association of iron indices and type 2 diabetes: a meta-analysis of observational studies. Diabetes Metab Res Rev. 2014;30(5):372-394.
Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab. 2013;17(3):329-341.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-454.
Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999;117(5):1155-1163.
Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care. 2007;30(7):1926.
Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J Hepatol. 2007;46(4):700-707.
Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients. 2017;9(4):387.
Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. J Hepatol. 2011;55(4):920-932.
Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care. 2004;27(10):2422.
Dinneen SF, Silverberg JD, Batts KP, O'Brien PC, Ballard DJ, Rizza RA. Liver iron stores in patients with non-insulin-dependent diabetes mellitus. Mayo Clin Proc. 1994;69(1):13-15.
Vari IS, Balkau B, Kettaneh A, et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population. Diabetes Care. 2007;30(7):1795.
O'Riordain MG, Ross JA, Fearon KC, et al. Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol. 1995;269(2 Pt 1):E323-E330.
Tanner LI, Lienhard GE. Insulin elicits a redistribution of transferrin receptors in 3T3-L1 adipocytes through an increase in the rate constant for receptor externalization. J Biol Chem. 1987;262(19):8975-8980.
Vargas L, Kawada ME, Bazaes S, Farplus PA, Faerman CH. Insulin antagonism: a novel role for human serum transferrin. Horm Metab Res. 1998;30(3):113-117.
Silva AM, Sousa PR, Coimbra JT, et al. The glycation site specificity of human serum transferrin is a determinant for transferrin's functional impairment under elevated glycaemic conditions. Biochem J. 2014;461(1):33-42.
Contributed Indexing:
Keywords: MRI; ferritin; impaired glucose metabolism; interaction; transferrin; type 2 diabetes
Substance Nomenclature:
E1UOL152H7 (Iron)
Entry Date(s):
Date Created: 20210308 Date Completed: 20210802 Latest Revision: 20210802
Update Code:
20240105
DOI:
10.1111/liv.14868
PMID:
33683798
Czasopismo naukowe
Background: Iron status has been linked with impaired glucose metabolism (IGM), type 2 diabetes mellitus (T2DM) and the metabolic syndrome (MetS), but the role of hepatic steatosis or iron overload on these associations remains uncertain.
Methods: We analysed data from 2310 participants without known T2DM of the population-based Study of Health in Pomerania (SHIP-TREND, Germany) through logistic regression models. We tested additive and multiplicative interactions between ferritin and hepatic steatosis or iron overload.
Results: Serum ferritin was positively associated with IGM (OR per 100 µg/L: 1.11 [1.01, 1.23]), T2DM (OR per 100 µg/L: 1.20 [1.06, 1.36]) and MetS (OR per 100 µg/L: 1.11 [1.02, 1.20]) in the total population as well as in participants without hepatic iron overload. However, the synergistic effect of higher ferritin concentrations and hepatic iron overload showed stronger associations with IGM and T2DM. Similarly, while ferritin was positively associated with T2DM and MetS even in the absence of hepatic steatosis, the synergistic effect of higher ferritin concentrations and hepatic steatosis showed stronger associations with IGM, T2DM and MetS. Transferrin was associated with isolated impaired glucose tolerance but not with T2DM and MetS.
Conclusions: Our study suggests that ferritin may be associated with glucose metabolism disorders and MetS even in people without hepatic steatosis or iron overload. However, in individuals with higher ferritin concentrations, the presence of hepatic steatosis may indicate stronger risk for glucose metabolism disorders and MetS, while the presence of hepatic iron overload may indicate stronger risk only for glucose metabolism disorders.
(© 2021 The Authors. Liver International published by John Wiley & Sons Ltd.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies